Pulmonary Complications Secondary to Immune Checkpoint Inhibitors

BACKGROUND: Immune checkpoint inhibitors (ICI) have changed the landscape in the treatment of a number of cancers. Immune-related adverse events (irAEs) have emerged as a serious clinical problem with the use of ICI. METHODS: All oncology patients diagnosed with pulmonary complications secondary to...

Descripción completa

Detalles Bibliográficos
Autores principales: Albitar, Hasan Ahmad Hasan, Duma, Narjust, Leventakos, Konstantinos, Gallo De Moraes, Alice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196156/
https://www.ncbi.nlm.nih.gov/pubmed/32373643
http://dx.doi.org/10.1155/2020/4928648

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196156/
https://www.ncbi.nlm.nih.gov/pubmed/32373643
http://dx.doi.org/10.1155/2020/4928648

Ejemplares similares